Perrigo Co. Stock Plummets to New 52-Week Low of $20.43

Perrigo Co. Plc, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 20.43 on October 30, 2025. This marks a significant decline for the company, which has seen its stock price drop by 24.28% over the past year, contrasting sharply with the S&P 500's performance of 18.13% during the same period.
The company's financial metrics reveal a challenging landscape. Perrigo's market capitalization stands at USD 3,072 million, and it currently operates at a loss, with a negative net profit of USD 67.46 million over the past nine months, reflecting a staggering decline of 202.37%. Additionally, the pre-tax profit for the most recent quarter has fallen by 90.52%, indicating ongoing difficulties in maintaining profitability.

Perrigo's debt-to-equity ratio is 0.72, and it offers a modest dividend yield of 0.04%. The price-to-book ratio is at 0.69, suggesting that the stock may be undervalued relative to its assets. However, the company has consistently underperformed against market benchmarks, raising concerns about its future performance in a competitive industry.